Ceritinib/crizotinibDevelopment of resistance in EML4-ALK-positive non-small cell lung cancer: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1635卷 / 1期
关键词：
D O I：
10.1007/s40278-017-25324-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 75
相关论文
共 50 条
  • [21] Brigatinib/crizotinibDevelopment of resistance to brigatinib and crizotinibin in non-small cell lung cancer: case report
    Reactions Weekly, 2019, 1780 (1) : 80 - 80
  • [22] The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
    Friboulet, Luc
    Li, Nanxin
    Katayama, Ryohei
    Lee, Christian C.
    Gainor, Justin F.
    Crystal, Adam S.
    Michellys, Pierre-Yves
    Awad, Mark M.
    Yanagitani, Noriko
    Kim, Sungjoon
    Pferdekamper, AnneMarie C.
    Li, Jie
    Kasibhatla, Shailaja
    Sun, Frank
    Sun, Xiuying
    Hua, Su
    McNamara, Peter
    Mahmood, Sidra
    Lockerman, Elizabeth L.
    Fujita, Naoya
    Nishio, Makoto
    Harris, Jennifer L.
    Shaw, Alice T.
    Engelman, Jeffrey A.
    CANCER DISCOVERY, 2014, 4 (06) : 662 - 673
  • [23] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement:a case report
    Ling Zhang
    Yunxia Li
    Shaohong Zhang
    Chen Gao
    Keke Nie
    Youxin Ji
    Cancer Biology & Medicine, 2018, (02) : 178 - 181
  • [24] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
    Zhang, Ling
    Li, Yunxia
    Zhang, Shaohong
    Gao, Chen
    Nie, Keke
    Ji, Youxin
    CANCER BIOLOGY & MEDICINE, 2018, 15 (02) : 178 - 181
  • [25] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement:a case report
    Ling Zhang
    Yunxia Li
    Shaohong Zhang
    Chen Gao
    Keke Nie
    Youxin Ji
    Cancer Biology & Medicine, 2018, 15 (02) : 178 - 181
  • [26] ANALYSIS OF EML4-ALK POSITIVE NON-SMALL CELL LUNG CANCER WITH ADVANCED STAGE
    Park, J.
    Kondo, C.
    Shimizu, J.
    Horio, Y.
    Yoshida, K.
    Yatabe, Y.
    Mitsudomi, T.
    Hida, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 433 - 434
  • [27] A NOVEL MASS SPECTROMETRY-BASED ASSAY FOR DIAGNOSIS OF EML4-ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
    Sakai, K.
    Okamoto, I.
    Takezawa, K.
    Hirashima, T.
    Kaneda, H.
    Takeda, M.
    Matsumoto, K.
    Kimura, H.
    Fujita, Y.
    Nakagawa, K.
    Arao, T.
    Nishio, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 103
  • [28] An experimental model for in vivo treatment with ALK inhibitors of EML4-ALK-positive lung cancer
    Soda, Manabu
    Takada, Shuji
    Takeuchi, Kengo
    Hatanaka, Hisashi
    Yamashita, Yoshihiro
    Ishikawa, Yuichi
    Sugiyama, Yukihiko
    Mano, Hiroyuki
    CANCER RESEARCH, 2009, 69
  • [29] RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report
    Yan, Huan
    Zeng, Liang
    Zhang, Yongchang
    HELIYON, 2024, 10 (09)
  • [30] Finding a place for ceritinib in the landscape of ALK-positive non-small cell lung cancer
    Shum, Elaine
    Gandhi, Leena
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S215 - S218
12345